IL2RA and rheumatoid arthritis: Xinqiang et al. suggested that the mechanism underlying the therapeutic efficacy of low-dose methotrexate, the current “gold standard” treatment in experimental RA, could be at least partially attributed to the increased production of CD4+CD25+ Treg cells.